Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation.
Atrial fibrillation (AF) is the most common form of cardiac arrhythmia and is associated with an increased risk of cardiovascular morbidity and mortality, especially due to ischemic stroke. The occurrence of AF leads to atrial electrical and structural remodeling. The renin-angiotensin system appears to play a role in the development of atrial arrhythmias by its involvement in both of these processes. Large-scale hypertension trials and heart failure trials have indicated the potential value of angiotensin II receptor blockers in the treatment of AF.
Penn State Heart and Vascular Institute, Hershey, Pennsylvania 17033-3907, USA. gnaccarelli@psu.edu
Gerald V
GV
Naccarelli
Frank
F
Peacock
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D004554:Electric Countershock; D019317:Evidence-Based Medicine; D006801:Humans; D012008:Recurrence; D012084:Renin-Angiotensin System / Q000187:drug effects*; D020521:Stroke / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D016896:Treatment Outcome
D047228:Angiotensin II Type 1 Receptor Blockers